Titre:
  • A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Auteur:Heath, Elisabeth I; Lorusso, Patricia; Ramalingam, Suresh S; Awada, Ahmad; Egorin, Merrill J; Besse-Hammer, Tatiana; Cardoso, Fatima; Valdivieso, Manuel; Has, Teresa; Alland, Leila; Zhou, Xiaofei; Belani, Chandra P
Informations sur la publication:Investigational new drugs, 29, 6, page (1426-1431)
Statut de publication:Publié, 2011-12
Sujet CREF:Cancérologie
Mots-clés:Oral
Paclitaxel
Phase I
MeSH keywords:Administration, Oral
Aged
Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics
Bridged Compounds -- administration & dosage -- adverse effects -- pharmacokinetics
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Neoplasms -- drug therapy -- pathology
Neutropenia -- chemically induced
Sepsis -- chemically induced
Treatment Outcome
Note générale:Clinical Trial, Phase I
Journal Article
Multicenter Study
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0167-6997
info:doi/10.1007/s10637-010-9498-z
info:scp/84856051059
info:pmid/20680660